BioAtla IPO Presentation Deck

ROR2 Targeting: Significant Commercial Opportunity ROR2 Over-expression 1 Over-expressed across many solid tumors, including NSCLC, melanoma, ovarian, TNBC, and HNC Tumor type NSCLC Melanoma Ovarian Cancer Enhanced ROR2 Expression 2 Patient treatment phase Stage III/IV (PD-1/L1 inhibitor) Immune checkpoint inhibitor Stage III/IV Platinum resistant Enhanced ROR2 expression with prior PD-1/L1 treatment Initial US Addressable Patient Population Est. corresponding US patient population 66,000² 25,000² 12,000 3 Nascent Competition Est. ROR2 positivity rate¹ 30% No other ROR2 ADC or small molecules in the clinic yet, but competition is emerging 20-30% 30-40% Source: BioAtia IHC assay validation results & phase 1 AXL testing data, GlobaiData-Opportunity Analysis and Forecasts, SEER database; Based on TmPS (Tumor membrane Percent Score) 75% of these patients generally switch to a new therapy bicatla Est. US target population at launch 15,000 5,000 4,000 16

View entire presentation